Skip to main content
. Author manuscript; available in PMC: 2022 Oct 6.
Published in final edited form as: Neuron. 2021 Aug 13;109(19):3104–3118.e6. doi: 10.1016/j.neuron.2021.07.018

Fig. 8: Fzd1 inhibition via UM206 promotes in vivo remyelination.

Fig. 8:

(A, B) MAG+ mRNA expressing cells at 10 dpl following lysolecithin induced corpus callosum focal demyelination with or without UM206 infusion in either Olig1cre: RZfl/fl mice or control RZfl/fl (non cre)(lesioning schematic Fig. S4C, S4D), and (B) quantification of MAG+ cells in lesion areas. Dotted line marks lesion extent in corpus callosum. * : compared to RZ fl/fl; #: compared to Olig1cre:RZ fl/fl. (C) DAPI staining identifies lesion areas in the same mice as above. (D) Olig2+ immunostaining in lesion areas from above mice, with quantification in (E). (F) Quantification (from EM) of myelinated axons in lesions at 14 dpl. * : compared to RZ fl/fl; #: compared to Olig1cre:RZ fl/fl. (G) EM of remyelination at 14 dpl from these same mice. (H) G-ratio analyses of remyelination at 14dpl (scatterplot displays g-ratios of individual axons. n=3 animals). Values in all graphs are mean±s.d. NS not significant, *p<0.05, ** p<0.01, *** p< 0.001, **** p<0.0001. Scale bars in all images are 100μm, except in (G) which is 1μm. See also Fig. S4 and S8.